Last edition
News about Drug Discovery & Development
Dupixent Approval in Japan Boosts Biologics Manufacturing Demand for Sanofi and Regeneron
The Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization to Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP), a rare and debilitating skin disorder.
Drug Discovery & Development | 25/03/2026 | By Darshana | 119
Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer
Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.
Drug Discovery & Development | 19/03/2026 | By News Bureau | 106
US FDA Pushes Shift Away from Animal Testing in Early Drug Studies
The U.S. Food and Drug Administration (FDA) is pushing for a shift away from animal testing in early-stage drug development, encouraging companies to adopt more modern and human-relevant methods.
Drug Discovery & Development | 19/03/2026 | By Darshana | 122
A National Institutes of Health-backed study shows weekly injectable buprenorphine improves opioid abstinence and reduces serious risks compared to sublingual treatment in pregnant women with opioid use disorder.
Drug Discovery & Development | 18/03/2026 | By News Bureau | 112
Shanghai UniXell Biotechnology. has received US Food and Drug Administration IND clearance for UX-GIP001, marking the first iPSC-derived allogeneic cell therapy to enter clinical trials for Epilepsy in the US.
Drug Discovery & Development | 17/03/2026 | By News Bureau | 172
KORU Medical Gains EU MDR Approval For Freedom60 Infusion Pump
KORU Medical Systems has announced that its Freedom60 Infusion Pump, including the adapter designed for use with 50 mL prefilled syringes, has received certification under the European Union Medical Devices Regulation (EU MDR 2017/745). The certification allows the company to commercialise the device across the European Union.
Drug Discovery & Development | 16/03/2026 | By Darshana | 109
Cbio A/S has received regulatory approval to begin a Phase I/IIa trial of novoleucel, a next-generation T-cell therapy, in patients with recurrent Cervical Cancer.
Drug Discovery & Development | 16/03/2026 | By News Bureau
Hutchmed Initiates Tazverik Recall In China After Ipsen Withdraws Drug In US
Hutchmed (China) Limited has begun withdrawing the cancer therapy Tazverik (tazemetostat) from markets in mainland China, Hong Kong and Macau after its partner Ipsen decided to voluntarily remove the drug from the US market.
Drug Discovery & Development | 11/03/2026 | By Darshana | 101
Citius Oncology reports positive Phase I data showing encouraging safety and response rates for LYMPHIR combined with Keytruda in recurrent gynecologic cancers, supporting further Phase II evaluation.
Drug Discovery & Development | 11/03/2026 | By News Bureau | 108
National Medical Products Administration approves IND application for HBM7575/SKB575, a long-acting bispecific antibody developed by Harbour BioMed and Kelun-Biotech for treating atopic dermatitis.
Drug Discovery & Development | 10/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy